89 related articles for article (PubMed ID: 21915857)
1. Fancf-deficient mice are prone to develop ovarian tumours.
Bakker ST; van de Vrugt HJ; Visser JA; Delzenne-Goette E; van der Wal A; Berns MA; van de Ven M; Oostra AB; de Vries S; Kramer P; Arwert F; van der Valk M; de Winter JP; te Riele H
J Pathol; 2012 Jan; 226(1):28-39. PubMed ID: 21915857
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway.
Wang Z; Li M; Lu S; Zhang Y; Wang H
Cancer Biol Ther; 2006 Mar; 5(3):256-60. PubMed ID: 16418574
[TBL] [Abstract][Full Text] [Related]
3. Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells.
Xie Y; de Winter JP; Waisfisz Q; Nieuwint AW; Scheper RJ; Arwert F; Hoatlin ME; Ossenkoppele GJ; Schuurhuis GJ; Joenje H
Br J Haematol; 2000 Dec; 111(4):1057-64. PubMed ID: 11167740
[TBL] [Abstract][Full Text] [Related]
4. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD
Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539
[TBL] [Abstract][Full Text] [Related]
5. No evidence of significant silencing of Fanconi genes FANCF and FANCB or Nijmegen breakage syndrome gene NBS1 by DNA hyper-methylation in sporadic childhood leukaemia.
Meyer S; White DJ; Will AM; Eden T; Sim A; Brown R; Strathdee G
Br J Haematol; 2006 Jul; 134(1):61-3. PubMed ID: 16803569
[TBL] [Abstract][Full Text] [Related]
6. Fancm-deficient mice reveal unique features of Fanconi anemia complementation group M.
Bakker ST; van de Vrugt HJ; Rooimans MA; Oostra AB; Steltenpool J; Delzenne-Goette E; van der Wal A; van der Valk M; Joenje H; te Riele H; de Winter JP
Hum Mol Genet; 2009 Sep; 18(18):3484-95. PubMed ID: 19561169
[TBL] [Abstract][Full Text] [Related]
7. Disruption of the FA/BRCA pathway in bladder cancer.
Neveling K; Kalb R; Florl AR; Herterich S; Friedl R; Hoehn H; Hader C; Hartmann FH; Nanda I; Steinlein C; Schmid M; Tonnies H; Hurst CD; Knowles MA; Hanenberg H; Schulz WA; Schindler D
Cytogenet Genome Res; 2007; 118(2-4):166-76. PubMed ID: 18000367
[TBL] [Abstract][Full Text] [Related]
8. Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice.
Houghtaling S; Granville L; Akkari Y; Torimaru Y; Olson S; Finegold M; Grompe M
Cancer Res; 2005 Jan; 65(1):85-91. PubMed ID: 15665282
[TBL] [Abstract][Full Text] [Related]
9. Involvement of Fanconi anemia genes FANCD2 and FANCF in the molecular basis of drug resistance in leukemia.
Yao C; Du W; Chen H; Xiao S; Huang L; Chen FP
Mol Med Rep; 2015 Jun; 11(6):4605-10. PubMed ID: 25647473
[TBL] [Abstract][Full Text] [Related]
10. RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation.
He M; Sun HG; Hao JY; Li YL; Yu JK; Yan YY; Zhao L; Li N; Wang Y; Bai XF; Yu ZJ; Zheng ZH; Mi XY; Wang EH; Wei MJ
Oncol Rep; 2013 May; 29(5):1721-9. PubMed ID: 23440494
[TBL] [Abstract][Full Text] [Related]
11. Genetic analysis of a Fanconi anemia case revealed the presence of FANCF mutation (exon 1;469>C-T) with implications to develop acute myeloid leukemia.
Behera CK; Gyandeep G; Mishra R; Mohanty RP; Pal A; Behera J; Samal S; Das B
Mol Biol Rep; 2023 Jan; 50(1):931-936. PubMed ID: 36369330
[TBL] [Abstract][Full Text] [Related]
12. The molecular biology of Fanconi anemia.
Tamary H; Bar-Yam R; Zemach M; Dgany O; Shalmon L; Yaniv I
Isr Med Assoc J; 2002 Oct; 4(10):819-23. PubMed ID: 12389351
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.
Seal S; Barfoot R; Jayatilake H; Smith P; Renwick A; Bascombe L; McGuffog L; Evans DG; Eccles D; Easton DF; Stratton MR; Rahman N;
Cancer Res; 2003 Dec; 63(24):8596-9. PubMed ID: 14695169
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma.
Wreesmann VB; Estilo C; Eisele DW; Singh B; Wang SJ
ORL J Otorhinolaryngol Relat Spec; 2007; 69(4):218-25. PubMed ID: 17409780
[TBL] [Abstract][Full Text] [Related]
15. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2.
Godthelp BC; van Buul PP; Jaspers NG; Elghalbzouri-Maghrani E; van Duijn-Goedhart A; Arwert F; Joenje H; Zdzienicka MZ
Mutat Res; 2006 Oct; 601(1-2):191-201. PubMed ID: 16920162
[TBL] [Abstract][Full Text] [Related]
16. Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer.
Lyakhovich A; Surralles J
Cancer Lett; 2006 Jan; 232(1):99-106. PubMed ID: 16246487
[TBL] [Abstract][Full Text] [Related]
17. Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia.
Tischkowitz M; Ameziane N; Waisfisz Q; De Winter JP; Harris R; Taniguchi T; D'Andrea A; Hodgson SV; Mathew CG; Joenje H
Br J Haematol; 2003 Nov; 123(3):469-71. PubMed ID: 14617007
[TBL] [Abstract][Full Text] [Related]
18. Effective CRISPR/Cas9-mediated correction of a Fanconi anemia defect by error-prone end joining or templated repair.
van de Vrugt HJ; Harmsen T; Riepsaame J; Alexantya G; van Mil SE; de Vries Y; Bin Ali R; Huijbers IJ; Dorsman JC; Wolthuis RMF; Te Riele H
Sci Rep; 2019 Jan; 9(1):768. PubMed ID: 30683899
[TBL] [Abstract][Full Text] [Related]
19. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.
Hussain S; Witt E; Huber PA; Medhurst AL; Ashworth A; Mathew CG
Hum Mol Genet; 2003 Oct; 12(19):2503-10. PubMed ID: 12915460
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.
Lim SL; Smith P; Syed N; Coens C; Wong H; van der Burg M; Szlosarek P; Crook T; Green JA
Br J Cancer; 2008 Apr; 98(8):1452-6. PubMed ID: 18414472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
